Masticatory Muscle Myositis (MMM) is an immune-mediated inflammatory myopathy that selectively affects the muscles of mastication in dogs.
Overview and Clinical Importance
Masticatory Muscle Myositis (MMM) is an immune-mediated inflammatory myopathy that selectively affects the muscles of mastication in dogs. It is the most common focal inflammatory myopathy in dogs and represents a significant topic for NAVLE examination due to its unique pathophysiology, distinctive clinical presentation, and specific diagnostic approach.
MMM is characterized by autoantibodies directed against type 2M muscle fibers, which are unique to the masticatory muscles. This specificity provides the basis for both the selective muscle involvement and the highly specific diagnostic test. Early recognition and aggressive immunosuppressive therapy are critical for optimal outcomes.
| Muscle |
Function |
Contains 2M Fibers |
Clinical Significance |
| Temporalis |
Jaw closure, mandible elevation |
Yes |
Most visible atrophy; preferred biopsy site |
| Masseter |
Jaw closure, powerful bite force |
Yes |
Swelling visible on cheeks; alternate biopsy site |
| Pterygoid (medial and lateral) |
Jaw closure, lateral movement |
Yes |
Swelling causes exophthalmos; atrophy causes enophthalmos |
| Digastricus (rostral portion) |
Jaw opening |
NO (type 2M fibers absent) |
Typically spared in MMM; helps differentiate from polymyositis |
Anatomy of the Masticatory Muscles
The muscles of mastication are the group of muscles responsible for jaw movement during chewing. They are all innervated by the mandibular branch of the trigeminal nerve (CN V). This shared innervation is significant because the masticatory muscles contain a unique myosin isoform (type 2M fibers) that is not present in other skeletal muscles.
Muscles Affected in MMM
High-YieldThe digastricus muscle does NOT contain type 2M fibers and is therefore typically spared in MMM. This is an important distinguishing feature from polymyositis, which affects all muscles including the digastricus. When imaging shows involvement of the digastricus, consider polymyositis over MMM.
| Parameter |
Details |
| Median Age |
3 years (range: 4 months to any age) |
| Sex Predisposition |
None; affects males and females equally |
| Size Predisposition |
Large breed dogs more commonly affected |
| Predisposed Breeds |
German Shepherd Dogs, Golden Retrievers, Labrador Retrievers, Doberman Pinschers, Rottweilers, Cavalier King Charles Spaniels, Weimaraners |
| Special Note: CKCS |
May present as young as 12 weeks; possible breed-specific variant with genetic predisposition |
Pathophysiology
MMM is a CD8+ T-cell mediated autoimmune disease characterized by the production of autoantibodies against type 2M muscle fibers. The masticatory muscles contain a unique myosin isoform found nowhere else in the body, which explains the selective involvement of these muscles.
Key Pathophysiologic Concepts
- Type 2M Muscle Fibers: Unique myosin heavy and light chains present only in masticatory muscles innervated by the mandibular branch of CN V
- Autoantibody Production: IgG antibodies target LC2-M (myosin light chain 2-masticatory), which has minimal cross-reactivity with limb muscle type 2A fibers
- Inflammatory Infiltration: Lymphocytic and plasmacytic infiltrates predominate, with perivascular distribution; eosinophils may be present but are not pathognomonic
- Disease Progression: Acute phase (inflammation and swelling) progresses to chronic phase (fibrosis and atrophy) if untreated
| Acute Phase |
Chronic Phase |
| Muscle Changes:
Bilateral swelling of temporalis and masseter muscles
Pain:
Severe jaw pain on palpation or attempted opening
Jaw Function:
Trismus (restricted jaw opening)
Ocular Signs:
Exophthalmos, third eyelid protrusion, conjunctival hyperemia |
Muscle Changes:
Bilateral atrophy with prominent skull bones
Pain:
Usually minimal to absent
Jaw Function:
Trismus persists due to fibrosis; mechanical restriction
Ocular Signs:
Enophthalmos (sunken eyes) due to loss of retrobulbar muscle mass |
Signalment and Epidemiology
NAVLE TipWhen you see a young, large breed dog (especially German Shepherd) presenting with jaw pain, difficulty eating, and facial muscle swelling or atrophy, MMM should be at the top of your differential list. Remember that CKCS puppies can present as young as 3-4 months of age with a possible juvenile variant.
| Condition |
Key Features |
How to Differentiate from MMM |
| Trigeminal Neuritis |
Dropped jaw (inability to CLOSE mouth); jaw hangs open |
MMM = cannot OPEN jaw (trismus); Trigeminal neuritis = cannot CLOSE jaw (dropped jaw); 2M antibody negative |
| Polymyositis |
Generalized muscle involvement including limb muscles; weakness; stiff gait |
2M antibody negative; limb muscle involvement on exam and biopsy; EMG shows generalized changes |
| Trigeminal Nerve Sheath Tumor |
UNILATERAL masticatory muscle atrophy; progressive; older dogs |
MMM typically bilateral; MRI shows nerve mass; 2M antibody negative |
| Temporomandibular Joint (TMJ) Disease |
Ankylosis, luxation, dysplasia, osteoarthritis |
Radiographs/CT show bony changes; no muscle swelling or atrophy; 2M antibody negative |
| Retrobulbar Abscess |
Unilateral exophthalmos; pain opening mouth; fever; often tooth root origin |
Oral exam reveals swelling behind last molar; imaging shows abscess; unilateral involvement |
| Tetanus |
Generalized muscle rigidity; risus sardonicus; history of wound |
Systemic rigidity; erect ears; anxious expression; no swelling/atrophy |
| Craniomandibular Osteopathy |
Young terrier breeds; bony proliferation of mandible and skull |
Radiographs show bony proliferation; no soft tissue changes; typical breed and age |
Clinical Signs
Acute Phase vs Chronic Phase
Additional Clinical Findings
- Systemic signs: Lethargy, pyrexia, weight loss, anorexia
- Lymphadenopathy: Mandibular and retropharyngeal lymph node enlargement
- Eating behavior: Difficulty prehending food, dropping food, inability to chew, ptyalism (drooling)
- Critical diagnostic finding: Inability to open jaw under general anesthesia (pathognomonic for MMM when combined with other signs)
High-YieldA classic NAVLE question stem: 'A dog presents for difficulty eating. On physical examination, there is bilateral masticatory muscle swelling and pain when attempting to open the jaw. Under general anesthesia, the jaw cannot be manually opened.' The inability to open the jaw under anesthesia is the key finding that distinguishes MMM from other causes of jaw pain.
| Test |
Expected Findings |
Clinical Significance |
| CBC |
Eosinophilia (variable); neutrophilic leukocytosis; mild anemia possible |
Eosinophilia NOT pathognomonic; inflammatory leukogram supports active disease |
| Serum Chemistry |
Elevated CK (creatine kinase); elevated AST; hyperglobulinemia |
CK may be normal or only mildly elevated; useful for monitoring response to therapy |
| C-Reactive Protein |
Elevated in acute phase |
Useful inflammatory marker for monitoring |
Differential Diagnosis
| 2M Antibody Result |
Interpretation |
| Negative (less than 1:100) |
Does not support MMM diagnosis; consider muscle biopsy if clinical suspicion high |
| Borderline (1:100) |
May indicate early MMM or recent steroid therapy lowering titer; recommend muscle biopsy |
| Positive (1:500, 1:1000, or 1:4000) |
DIAGNOSTIC for MMM - 100% specific; proceed with treatment |
Diagnostic Approach
Step 1: Minimum Database
Step 2: Definitive Diagnosis - 2M Antibody Test
The 2M antibody ELISA is the gold standard diagnostic test for MMM. This test detects circulating autoantibodies against type 2M muscle fibers and is available through the Comparative Neuromuscular Laboratory at UC San Diego.
High-YieldCRITICAL: The 2M antibody test MUST be performed BEFORE starting corticosteroid therapy! Immunosuppressive doses of corticosteroids for more than 7-10 days will therapeutically lower antibody titers, resulting in FALSE NEGATIVES. If steroids have already been started, a muscle biopsy is required for diagnosis.
Causes of False Negative 2M Antibody Test
- Prior corticosteroid therapy (more than 7-10 days at immunosuppressive doses)
- End-stage disease with complete destruction of 2M fibers and marked fibrosis
- Sample handling issues (hemolysis, severe lipemia)
- Approximately 10-15% of true MMM cases may test negative
Step 3: Muscle Biopsy (When Indicated)
Temporalis muscle biopsy provides both diagnostic confirmation and prognostic information about the degree of fibrosis and remaining muscle mass.
Biopsy Technique Tips
- CRITICAL: Incise through the frontalis muscle first, then through the thick fascia overlying the temporalis - do NOT sample the frontalis muscle as it is not affected in MMM
- Collect two samples: one fresh-frozen for immunohistochemistry, one in formalin for histopathology
- Contact laboratory for specific submission requirements before collecting
Histopathologic Findings
- Acute phase: Lymphocytic-plasmacytic infiltration (perivascular), myofiber necrosis, phagocytosis, eosinophils may be present
- Chronic phase: Myofiber atrophy, replacement with fibrous and fatty tissue, reduced inflammation
Advanced Imaging (When Needed)
MRI Findings
MRI is the most sensitive imaging modality for detecting early MMM and is useful when 2M antibody results are equivocal.
- T1-weighted: Iso- to hypointense signal in affected muscles
- T2-weighted/FLAIR/STIR: Hyperintense signal in temporalis, masseter, and pterygoid muscles (bilateral, often asymmetric)
- Post-contrast: Heterogeneous contrast enhancement of affected muscles
- Digastricus: Typically spared (helps differentiate from polymyositis)
CT Findings
- Changes in muscle size (swelling in acute; atrophy in chronic)
- Hypoattenuation of affected muscles on pre-contrast images
- Inhomogeneous contrast enhancement
- Regional lymphadenomegaly
| Phase |
Prednisone Dosage |
Duration/Notes |
| Induction (Acute) |
1-2 mg/kg PO q12h (immunosuppressive dose) |
Continue until pain resolves, jaw mobility normalizes, and CK normalizes (typically 2-4 weeks) |
| Initial Taper |
Reduce by 25-50% every 2-4 weeks |
Monitor clinical signs; slow taper if relapse |
| Maintenance |
Lowest effective dose, ideally alternate-day dosing |
Continue for 4-6 months minimum; some dogs require lifelong therapy |
| Chronic Phase |
0.25-0.5 mg/kg PO q24h for 1 month, then taper |
Lower doses may be sufficient if significant fibrosis present |
Treatment
The cornerstone of MMM treatment is aggressive immunosuppressive therapy with corticosteroids. Early treatment before significant fibrosis develops is critical for optimal outcomes.
First-Line Therapy: Corticosteroids
Second-Line/Adjunctive Immunosuppressive Agents
Consider adding these agents if: steroid side effects are intolerable, inadequate response to steroids alone, rapid tapering is needed, or relapses occur during steroid taper.
Supportive Care
- Dietary modification: Soft or blended food; warm water added to kibble; elevated feeding may help
- Pain management: NSAIDs contraindicated with steroids; gabapentin or tramadol if needed
- Physical therapy: Encourage chewing on tennis balls, chew toys once pain resolves to improve jaw range of motion
- NEVER: Forcibly open the jaw - can cause fracture or dislocation
NAVLE TipThe most common cause of treatment failure in MMM is INAPPROPRIATE THERAPY: (1) Using anti-inflammatory rather than immunosuppressive steroid doses, (2) Tapering too quickly, or (3) Stopping treatment prematurely. Emphasize to clients that 4-6 months of treatment is typical, and some dogs need lifelong therapy.
| Drug |
Dosage |
Monitoring/Notes |
| Azathioprine |
2 mg/kg PO q24h initially, then q48h |
CBC monitoring monthly; watch for bone marrow suppression |
| Cyclosporine |
5 mg/kg PO q12h |
GI side effects common; can monitor trough levels |
| Mycophenolate Mofetil |
10 mg/kg PO q12h |
GI side effects; monitor CBC |
| Leflunomide |
2-3 mg/kg PO q24h |
CBC monthly; trough level after 10 days |
| Oclacitinib (novel) |
1 mg/kg PO q12h |
JAK-1 inhibitor; recent studies show promise as alternative to steroids |
Prognosis
High-YieldKey prognostic factors: (1) Stage at diagnosis (acute vs chronic), (2) Degree of fibrosis on biopsy, (3) Response to initial therapy, (4) Owner compliance with long-term treatment. The muscle biopsy provides the best prognostic information about potential for recovery of jaw function.
| Scenario |
Expected Outcome |
| Early diagnosis, acute phase, aggressive treatment |
GOOD prognosis; 91% return of jaw function; improvement within 1-3 days of treatment; most regain full function within 4 weeks |
| Chronic phase with established fibrosis |
GUARDED prognosis; permanent trismus and muscle atrophy likely; treatment can prevent further deterioration |
| Relapse during or after treatment |
Occurs in approximately 27% of cases; more difficult to manage; may require continued low-dose therapy |
| Young dogs (e.g., CKCS puppies) |
May have better regenerative capacity; good outcomes reported even with chronic presentation |